BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript

Our growth, excluding currency effects, was 12% versus a year ago, and our EBIT margin is 30% with an adjusted EBIT margin of 33% for the quarter. Overall, our net sales reached SEK 441 million, as I said, with growth, excluding currency effects of 12%. Specifically in the regions, in Europe, Middle East, Africa, our sales increased by 21%, excluding currency effects. In the Americas, increased by 16%, excluding currency effects, while Asia Pacific decreased by 6%, excluding currency effects due to order variability. Our operating profit in the quarter was SEK 132 million, which is an increase of 22% and our EBIT margin was 30% versus the 27% last year for Q2. Our adjusted EBIT margin was 33% for the quarter. Overall, our net sales year-to-date reached SEK 813 million, which is growth excluding currency effects of 13%. Our BioGaia company strategy remains the same. Our first strategic pillar is Grow the Core, the core being our core health areas of the business, of which Gut Health, which includes colic, oral health and immune health are our biggest priorities. Our second strategic pillar is what we call